jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
jemperli 500 mg/10 ml concentrato per soluzione per infusione
glaxosmithkline ag - dostarlimabum - concentrato per soluzione per infusione - dostarlimabum 500 mg, natrii citras dihydricus, acidum citricum monohydricum, arginini hydrochloridum, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 22.78 mg. - endometriumkarzinom - biotechnologika
meron plus ac
voco gmbh - cementi provvisori e definitivi da restauro odontoiatrico